VIAject: Completed Phase III enrollment

Biodel completed enrollment of a total of >400 patients with Type II diabetes in an open-label, international Phase III trial comparing VIAject vs. Humulin from Eli Lilly and Co. (NYSE:LLY, Indianapo...